What if we could treat metabolic diseases without the common side effects?
I’m excited to announce that my PhD research has been published in Nature! This work focuses on Neurokinin 2 Receptor (NK2R), a new drug target for metabolic disease.
🧵 https://t.co/Oslth0bZL8

— Frederike Sass (@SassFrederike) November 14, 2024